APA (7th ed.) Citation

Mansilla-Polo, M., García-Moronta, C., Fernández-Crehuet, P., Garbayo-Salmons, P., Pons-Benavent, M., Aguilar-González, L., . . . Molina-Leyva, A. (2025). Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response. Dermatology & Therapy, 15(11), 3267. https://doi.org/10.1007/s13555-025-01521-z

Chicago Style (17th ed.) Citation

Mansilla-Polo, Miguel, et al. "Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response." Dermatology & Therapy 15, no. 11 (2025): 3267. https://doi.org/10.1007/s13555-025-01521-z.

MLA (9th ed.) Citation

Mansilla-Polo, Miguel, et al. "Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response." Dermatology & Therapy, vol. 15, no. 11, 2025, p. 3267, https://doi.org/10.1007/s13555-025-01521-z.